

Accepted Manuscript

Novel, Highly Potent Systemic Glucokinase Activators for the Treatment of Type II Diabetes Mellitus

Jiayi Xu, Songnian Lin, Robert W. Myers, George Addona, Joel P. Berger, Brian Campbell, Hsuan-shen Chen, Zhesheng Chen, George J. Eiermann, Nadine H. Elowe, Brian T. Farrer, Wen Feng, Qinghong Fu, Roman Kats-Kagan, Michael Kavana, Sunita Malkani, Daniel R. McMasters, Kaushik Mitra, Michele J. Pachanski, Xinchun Tong, Maria E. Trujillo, Libo Xu, Bei Zhang, Fengqi Zhang, Rui Zhang, Emma R. Parmee



PII: S0960-894X(16)31133-7
DOI: <http://dx.doi.org/10.1016/j.bmcl.2016.10.085>
Reference: BMCL 24388

To appear in: *Bioorganic & Medicinal Chemistry Letters*

Received Date: 15 August 2016
Revised Date: 26 October 2016
Accepted Date: 28 October 2016

Please cite this article as: Xu, J., Lin, S., Myers, R.W., Addona, G., Berger, J.P., Campbell, B., Chen, H-s., Chen, Z., Eiermann, G.J., Elowe, N.H., Farrer, B.T., Feng, W., Fu, Q., Kats-Kagan, R., Kavana, M., Malkani, S., McMasters, D.R., Mitra, K., Pachanski, M.J., Tong, X., Trujillo, M.E., Xu, L., Zhang, B., Zhang, F., Zhang, R., Parmee, E.R., Novel, Highly Potent Systemic Glucokinase Activators for the Treatment of Type II Diabetes Mellitus, *Bioorganic & Medicinal Chemistry Letters* (2016), doi: <http://dx.doi.org/10.1016/j.bmcl.2016.10.085>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Novel, Highly Potent Systemic Glucokinase Activators for the Treatment of Type II Diabetes Mellitus


Jiayi Xu*, Songnian Lin*, Robert W. Myers, George Addona, Joel P. Berger, Brian Campbell, Hsuan-shen Chen, Zhesheng Chen, George J. Eiermann, Nadine H. Elowe, Brian T. Farrer, Wen Feng, Qinghong Fu, Roman Kats-Kagan, Michael Kavana, Sunita Malkani, Daniel R. McMasters, Kaushik Mitra, Michele J. Pachanski, Xinchun Tong, Maria E. Trujillo, Libo Xu, Bei Zhang, Fengqi Zhang, Rui Zhang, and Emma R. Parmee

Discovery, Preclinical and Early Development, Merck & Co., Inc., 2015 Galloping Hill Rd, Kenilworth, NJ USA

*Corresponding authors. Tel.: +1 732 594 1438; fax: +1 732 594 2840; Email: Jiayi_xu@merck.com (J. Xu). Tel.: +1 908 740 0585; fax: +1 908 740 3126; Email: songnian_lin@merck.com (S. Lin)


Abstract

Glucokinase (GK, hexokinase IV) is a unique hexokinase that plays a central role in mammalian glucose homeostasis. Glucose phosphorylation by GK in the pancreatic β -cell is the rate-limiting step that controls glucose-stimulated insulin secretion. Similarly, GK-mediated glucose phosphorylation in hepatocytes plays a major role in increasing hepatic glucose uptake and metabolism and possibly lowering hepatic glucose output. Small molecule GK activators (GKAs) have been identified that increase enzyme activity by binding to an allosteric site. GKAs offer a novel approach for the treatment of Type 2 Diabetes Mellitus (T2DM) and as such have garnered much attention. We now report the design, synthesis, and biological evaluation of a novel series of 2,5,6-trisubstituted indole derivatives that act as highly potent GKAs. Among them, Compound **1** was found to possess high *in vitro* potency, excellent physicochemical properties, and good pharmacokinetic profile in rodents. Oral administration of Compound **1** at doses as low as 0.03 mg/kg led to robust blood glucose lowering efficacy in 3 week high fat diet-fed mice.



hGK EC₅₀ (@2.5 mM glucose) = 3.7 nM; Max activity = 784%

hGK EC₅₀ (@10 mM glucose) = 2.4 nM; Max activity = 193%



Download English Version:

<https://daneshyari.com/en/article/5156466>

Download Persian Version:

<https://daneshyari.com/article/5156466>

[Daneshyari.com](https://daneshyari.com)